To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
Phase 3
Completed
NCT03676192
| Condition | Adenocarcinoma of Lung |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Celltrion |
|---|
| Status | Completed |
|---|
| Enrollment | 689 participants |
|---|
| Interventions | CT-P16, Avastin |
|---|
| Start date | Feb 1, 2019 |
|---|
| Completion date | Apr 22, 2021 |
|---|
| Results posted | Mar 17, 2025 |
|---|
Summary
To demonstrate that CT-P16 is similar to EU-Approved Avastin in terms of efficacy as determined by objective response rate (ORR) during the Induction Study Period
Objective Response Rate (ORR) During the Induction Study Period From Central Review
Induction Study Period (around 18 weeks) · percentage of responders
| CT-P16 | 42.40 percentage of responders |
|---|
| Avastin | 42.07 percentage of responders |
|---|
| Risk Difference (RD) | 0.40 (95% CI -7.02–7.83) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.